58 citations
,
May 2004 in “British Journal of Dermatology” Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.
2 citations
,
January 2025 in “Сибирский научный медицинский журнал” TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
12 citations
,
May 2015 in “Journal of the National Comprehensive Cancer Network” Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.
January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.
RCVS should be considered in thunderclap headaches, and MRA and DSA are better for diagnosis than CT angiogram.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
116 citations
,
December 2003 in “Acta Dermato Venereologica” Iressa often causes skin issues like acne and dryness in lung cancer patients.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
May 2024 in “Deleted Journal” Cancer treatments can cause hair loss, but it is often reversible and can be managed with scalp cooling and support.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
51 citations
,
August 2021 in “Turkish Journal of Medical Sciences” As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
September 2023 in “HAL (Le Centre pour la Communication Scientifique Directe)” Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
The balance between cell renewal and differentiation controls the growth of cancerous cells in mouse skin.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
February 2026 in “Reports — Medical Cases Images and Videos” Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
1 citations
,
March 2004 in “Journal of the American Academy of Dermatology” ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
9 citations
,
November 2023 in “Supportive Care in Cancer” This retrospective cohort study investigated 28 breast cancer patients who developed alopecia due to CDK4/6-inhibitor therapy, termed CDKiA. The alopecia resembled androgenetic alopecia, with more pronounced vertex involvement in patients receiving combination therapy with CDK4/6i and endocrine therapy (ET) compared to those on endocrine monotherapy. After 4-6 months of minoxidil treatment, 80% of CDKiA patients showed moderate to significant improvement, while 94.4% of those with endocrine-induced alopecia (EIA) improved. The study suggests that combining minoxidil with topical antiandrogens may be beneficial for CDKiA patients, especially due to the specific vertex involvement.
1 citations
,
April 2020 in “Journal of the Endocrine Society” Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
19 citations
,
April 2016 in “Case Reports in Dermatology” Nilotinib can cause keratosis pilaris, a skin condition.
4 citations
,
December 2024 in “JAAD Case Reports” Nirogacestat can cause severe skin issues like hidradenitis suppurativa.